PatientID: HDR121

Okitobba 06, 2023

Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	S	
	DRV	\mathbf{S}	
	FPV	\mathbf{S}	
	IDV	\mathbf{S}	
	LPV	${f S}$	
	NFV	${f S}$	
	SQV	${f S}$	
	TPV	\mathbf{S}	
NRTI	ABC	$_{ m LR}$	
	AZT	IR	
	D4T	IR	
	DDI	LR	M184V;T215F
	FTC	$_{ m HR}$	
	LMV	$_{ m HR}$	
	TDF	\mathbf{S}	
NNRTI	DOR	$_{ m HR}$	
	EFV	$_{ m HR}$	
	ETR	$_{ m HR}$	A98G;Y181C;G190S;H221Y;K238N
	NVP	$_{ m HR}$	
	RPV	$_{ m HR}$	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS			
PI				
	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate			
	resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to			
	continued treatment with 3TC or FTC because they increase susceptibility to AZT and			
NRTI	TDF and are associated with clinically significant reductions in HIV-1 replication.			
	T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially			
	low-level resistance to ABC and TDF.			
	A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.			
	G190S is a non-polymorphic mutation that confers high-level resistance to NVP and EFV.			
	It may also be associated low-levels reductions in DOR susceptibility. It does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility.			
	H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and			
	DOR. It frequently occurs in combination with Y181C.			
	K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP			
	and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal			
	effects on NNRTI susceptibility.			

NNRTI

	Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and
	low-level resistance to EFV. It does not significantly reduce DOR susceptibility.
INSTI	